Floatz logo

bnt162b2

Multiple Sclerosis

Griffin HospitalvaccinePhase 2Active
CC
44/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
65/ 100

Competitive context

177 Active assets in the Multiple Sclerosis cohort.

Asset / SponsorPhaseRating
Cladribine
University Hospital, Strasbourg, France
Phase 4BBB
Nabiximols
Jazz Pharmaceuticals
Phase 4BBB
Ocrevus
Polpharma Biologics International AG
Phase 4BBB
Teriflunomide
Sanofi
Phase 4BBB
Fampridine
MGH Institute of Health Professions
Phase 4BBB

View all 50 →

Same molecule, other indications

bnt162b2 is also rated in:

multiple sclerosisDormant
CC
Indicative ·
43 / 100
View asset →
rheumatoid arthritisDormant
CC
Indicative ·
43 / 100
View asset →
systemic lupus erythematosusDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →